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Loranthus micranthus (LM), also called African mistletoe is a major Nigerian Loranthaceae plant used traditionally to treat
hypertension. The methanolic leaf extract of the plant (LMME) has been shown to elicit anti-hypertensive activity in rats but
mechanism remains unclear. This study was undertaken to study the eﬀect of LM on pressor-induced contraction of rat aorta
smooth muscles and serum lipid proﬁles in mice. The LMME was partitioned to produce n-butanol (NBF-LMME), chloroform
(CF-LMME), ethyl acetate (EAF-LMME) and water (WF-LMME) fractions. The median eﬀective concentrations and maximum
relaxation of the fractions were determined against epinephrine and KCl pre-contracted rat aorta ring model. Serum lipid proﬁles
and nitric oxide (NO) were determined spectrophotometrically in mice administered per orally 250mg/kg b.w. of each fraction
for 21 days. Data were analyzed statistically. NBF-LMME elicited the highest dose-dependent inhibitory eﬀect on rat aorta pre-
contracted with norepinephrine and KCl, followed in decreasing order by WF-LMME > CF-LMME > EAF-LMME. Similar order
of activity was observed in the ability of these fractions to inhibit elevation in artherogenic lipids, raise serum nitric oxide and
reduce cardiac arginase in mice. We conclude the anti-hypertensive activity of L. micranthus involve anti-artherogenic events,
vasorelaxation, cardiac arginase reduction and NO elevation.
1.Introduction
Hypertension, classically deﬁned as systolic pressure
>165mmHg or diastolic blood pressure >95mmHg or both
inadultisanoninfectiousdiseaseofglobaldimensioninpre-
valence, incidence, complications, and deaths [1, 2]. Deaths
due to hypertension arise from cerebrovascular and car-
diovascular complications such as stroke, end-stage renal
disease, congestive heart failure, myocardial infarction, and
cardiac arrest [2]. Early detection and commencement of
chemotherapy are essential in preventing or delaying these
complications and enhancing survival of the aﬄicted pa-
tients [3]. To treat hypertension coupled with associated
complications, use has been made of drugs derived from
plants. They include digitoxin from Digitalis purpurea
(foxglove), reserpine from Rauwolﬁa serpentina (snakeroot),
aspirin from Salix alba (willow bark), tetramethylpyrazine,
also known as Ligustrazine from Jatropha podagrica, and
tetrandrine from Stephenia tetradra [4, 5]. These plant-
derived pharmaceuticals have scientiﬁcally been proven to
elicit antihypertensive activity via multiple mechanisms.
These mechanisms are elicited to counteract the eﬀect of
hypertension and associated risk factors such as hypercho-
lesterolemia, hypertriglyceridaemia, and oxidative stress on
blood vessel walls [6]. They include direct vasodilation of
the blood vessel, blocking of calcium channels, inhibition
of α-adrenoreceptor response, induction of negative iono-
tropic response of smooth muscle, inhibition of platelet ag-
gregation,reductionofvascularresistance,andimprovement
of pulmonary oxygen utilization [7–9]. Enhanced activity of2 Biochemistry Research International
nitric oxide and improved handling of intracellular calcium
has also been found to play a critical role in the reduction of
vascular resistance and blood pressure that are elevated in
hypertensive rats and humans [10, 11]. In the last 2 decades,
plants have remained historically important as sources of
novel compounds with potentials of being channeled into
drug pipelines for the development of safe, eﬃcacious, and
cost-eﬀective antihypertensive drugs. In sub-Saharan Africa,
the initial ethnopharmacological surveys have identiﬁed
over 100 species of plants with antihypertensive activity in
animals and humans [12, 13]. Loranthus micranthus from
the Loranthaceae family is one of these plants. The plant
is a semiparasitic shrub that grows by obtaining nutrients
a n ds u p p o r tf r o mah o s to ft r e e ss u c hKola acuminata,
K. nitida, Mangifera indica, Azadirachta indica, Jatropha cur-
cas, and Persia sp. in Nigeria [14]. The plant has for many
y e a r sb e e nd o c u m e n t e db o t hi nN i g e r i aa n dS o u t hA f r i c a
tobeatraditionalmedicineofhighreputeinthetreatmentof
diabetesandhypertension,asaremedyagainstschizophrenia
and an immune booster [15, 16] .As t u d yb yO b a t o m ie ta l .
[17] revealed hypotensive eﬀect of L. micranthus on spon-
taneously induced hypertensive rats. Other Loranthaceae
plants that have been validated to be hypotensive in function
include L. ferruginea, L. yadoriki and L. tanakee [18–20].
In our recent work, we found the methanolic leaf extract
of L. micranthus to elicit a dose-dependent inhibition of
blood pressure elevation in adrenaline induced hypertensive
rat (Iwalokun et al., unpublished) to corroborate previous
reports [15, 17]. Recently, Ameer et al. [21] reported the
n-butanol fraction from the methanolic leaf extract of
L. ferrugineus was found to elicit dose-dependent inhibition
of KCl and phenylephrine induced aortic ring contraction
coupled with blood pressure lowering eﬀect in rats. There-
fore, we hypothesize that mechanisms exist to mediate the
hypotensive action of L. micranthus, which remain largely
unknown. Meanwhile, the use of L. micranthus in animals
has been found to be safe with an LD50 >5000mg/kg [16]
andwithoutadversebiochemicaleﬀectsinrats[22].Aqueous
and methanolic leaf extracts of L. micranthus also contain
tannins, terpenoids, ﬂavonoids, and alkaloids phytocon-
stituents, which have been implicated for the various phar-
macologicalactivitiesoftheplantincludingantibacterialand
antidiabetic properties [14–16, 23, 24]. Interestingly, these
phytoconstituents were also found in other Loranthaceae
plants in association with antihypertensive activity [18–
20]. Given the long-term use of L. micranthus as an anti-
hypertensive plant, it is undoubtedly important to under-
stand its mechanisms of action in order to advance its po-
tential as a source of novel compounds for future de-
velopment of antihypertensive drugs. In this study, the vas-
cular eﬀects of diﬀerent fractions obtained by solvent-
solvent fractionation of crude methanolic leaf extract of L.
micranthus were investigated using isolated rat aortic ring
preparation under KCl and epinephrine induction. The
eﬀect of chronic administration of these fractions, including
the crude methanolic extract on blood lipid proﬁles, and
nitric oxide levels were also studied.
2.MaterialsandMethods
2.1. Plant Material. Aerial part of the plant Loranthus mi-
cranthuswas harvested from a Kolanut tree (Kola acuminata)
from Sagamu, Ogun State, during the beginning of rainy
season in March, 2009. The plant was taken to the Depart-
ment of Botany, University of Lagos, Nigeria for authenti-
cation. After authentication, a voucher sample of the plant
(no. 0184) was deposited in the herbarium of the University.
2.2. Preparation of Loranthus micranthus Methanolic Leaf
Extracts (LMME) and Its Fractions. The leaves of Loranthus
micranthus were rinsed in distilled water to remove dirt,
dried in an air-oven at 40◦C for 3 days, and then pulverized
into ﬁne powder that passed through a 30-mesh sieve. The
ground plant material (100g) was subsequently extracted
with 1000mL of 80% methanol using Soxhlet apparatus.
The resulting crude methanolic extract was ﬁltered by
passage through a Whatmann no. 3 ﬁlter paper followed by
concentration in vacuo at 40◦C using a rotary evaporator
and freeze drying. The yield of the freeze-dried sample
representing LMME was calculated to be 10.3%. For
the preparation of LMME fractions, 10g of the freeze-
dried sample was suspended in 150mL deionized water
and mixed thoroughly. The mixture was transferred to
a 1L-separating funnel for sequential fractionation by
solvent-solvent extraction method with sequential addition
of chloroform (4×100mL), ethylacetate (4×100mL), and
n-butanol (4×100mL). The resulting fractions collected
into separate conical ﬂasks were concentrated in vacuo
and subsequently freeze-dried to obtain 3.3g, 1.4g, 2.9g,
and 2.4g of chloroform (CF-LMME), ethylacetate (EAF-
LMME), n-butanol (NBF-LMME), and water (WF-LMME)
fractions, respectively. Another portion of the ground plant
material (50g), extracted with methanol, fractionated, and
freeze-dried as described previously was submitted to Phy-
tochemical screening according to Sofowora [25], Trease and
Evans [26], and Harborne [27]. Standard solutions of sap-
onin, nicotine, quercetin, and tannic acid (10mg/mL each)
from Sigma (USA) were prepared fresh as qualitative stand-
ards for saponins, alkaloids, ﬂavonoids and tannin, respec-
tively. Positive reactions were qualitatively graded as mildly
present (+), moderately present (++), and highly present
(+++) based on color intensity.
2.3. Animals and Chronic Administration of LMME Fractions.
Albino mice weighing between 21–23g (mean weight) and
rats (90–105g, mean weight = 97.4g) obtained from the
animal Facility of the Nigerian Institute of Medical Research
(NIMR),Yaba-Lagos,Nigeria were usedforthein vivo and in
vitro experiments, respectively. Experimentation was carried
out according to the National Institute of Health (USA)
guidelines on the care and use of laboratory animals for
experiments [28], while the study protocol was approved by
the Animal Committee of the National Institute of Medical
Laboratory Sciences, Nigeria. The animals were individually
housed in stainless metabolic cages under standard environ-
mental conditions of temperature (26 ± 1◦C) and humidityBiochemistry Research International 3
(60%–65%). They were placed on 12h light-dark cycle and
fed with standard rodent diets (Ladoke Feeds, Nigeria) with
deionized water ad libitum. The animals were acclimatized
in this manner for 7 days prior to use for experimentation.
On the 8th day, the acclimatized mice were fasted for 10h
but with access to water. Two mice were randomly selected
and sacriﬁced after a light chloroform anaesthesia to collect
whole blood by cardiac puncture into plain tubes for base-
line determination of lipid, nitric oxide and creatinine levels.
In a fasted state, the mice were randomized into 5 groups of
7 mice per group. Animals in groups I–IV were administered
per orally with 250mg/kg of body weight doses each
of CF-LMME, EAF-LMME, NBF-LMME, and WF-LMME
(dissolved in 200uL of normal saline) daily (10.00-11.00h)
for 21 days using an oral cannula. Animals in group V
received the vehicle (i.e., 200uL of normal saline (0.85%
NaCl)) in parallel with the extract treated mice. The animals
had free access to feed and deionized water throughout the
experimental period.
2.4. Biochemical Assays. On day 22, after a 10h fast but with
access to deionized water, the animals in groups 1-V were
sacriﬁced by cervical dislocation after light chloroform an-
aesthesia. Blood samples collected from each animal by car-
diac puncture into plain tubes were allowed to clot and
tubes were subsequently centrifuged at 2000rpm for 5min
to obtain sera that were transferred into new tubes and
kept at 20◦C until used for bioassays. The heart tissue was
immediately excised, rinsed in deionised water, blotted
dry between ﬁlter paper, and weighed. The weighed tissue
was homogenized in 3mL of ice-cold Tris-HCl buﬀer (pH
7.5) containing 0.08M MnCl2 for preactivation of cardiac
arginase using a glass homogenizer. After a preincubation for
30min, cardiac arginase was assayed as described by Gayer
and Dabich [29] using arginine (pH 9.5) at 37◦Ca sa
substrate. This method was based on the colorimetric de-
termination at 490nm of released urea nitrogen following
reaction with 2,3-butanedione. One unit of enzyme releases
one micromole of urea per minute under the assay condi-
tions. Enzyme activity was expressed as units/g tissue. Serum
total cholesterol was assayed as described by Siedel et al.
[30], while the protocols of T. Gordon and M. Gordon [31]
and Jacobs and VanDenmark [32] were adopted for the
determination of HDL-cholesterol and triglycerides (TAG).
LDL-cholesterol level was determined by calculation using
the Friedwald formula [33] as follows:
LDL-cholesterol
= Total cholesterol (TC) −
TAG
5
−HDL-cholesterol.
(1)
Serum creatinine and total protein were determined using
the alkaline picrate reagent [34] and biuret method [35].
Serum nitric oxide level was determined indirectly as its
metabolicproducts(nitrate+nitrite ions)spectrophotomet-
rically using a test kit (Boeringher, USA) in which all the
nitrate ions in serum were ﬁrst reduced to nitrite ions by
nitrate reductase followed by the reaction between nitrite
ions and the Greiss reagent (0.1% naphthylethylenediamine
dihydrochloride in distilled water and 1% sulfanilamide in
5% H3PO4)t of o r mab l u ec o l o rs o l u t i o n[ 36]. Absorbance
measurement was done at 540nm against the reagent blank
in which the serum sample was replaced with de-ionized
water. The levels of nitric oxide in the experimental ani-
mals and control were determined by extrapolation from
absorbance-concentration curve of the sodium nitrate stan-
dard solution (10–100μM).
2.5. Isolated Rat Aorta Ring Experiment. In this in vitro
experiment, the acclimatized rats were each anaesthetized
intraperitoneally with phenobarbitone sodium (60mg/kg
body weight), bled and exsanguinated. A midline incision
wasmadethroughthesternumtoopenupthethoraciccavity
and excise the aorta. Each aorta was sectioned into 4 rings of
3.5mm long devoid of fat and connective tissue. The rings
were placed horizontally in a tissue bath 10mL of Kreb’s-
Ringer-Bicarbonate (KRB) buﬀer (pH 7.4) (118.2mM NaCl,
4.7mM KCl, 2.5mM CaCl2·2H20, 1.2mM MgSO4,1 . 2m M
KH2PO4, 11.7mM glucose, and 25mM NaHCO3)u n d e r
5% CO2 and 95% O2 atmosphere at 37◦C. The aorta
rings were maintained under a 1.5g tension and allowed
to equilibrate for 30min prior to contraction induction
with KCl and norepinephrine. The tension was supplied
by a force-displacement transducer (model FT-03) that was
coupled with a data acquisition system and a computer (AD
Instrument, Sydney, Australia) and was connected to the
tissue bath. During the equilibration period, two changes
with fresh KRB (10mL each) in the tissue bath were made
to protect the aorta rings from toxicity that may arise from
metabolic waste products. Contraction of the aorta ring
smooth muscle was induced in separate experiments with
1uM and 80mM of norepinephrine and KCl, respectively.
In each experiment, precontraction of the aorta ring was
followed by cumulative addition of 0–1.5mg/mL each of the
LMME fractions: NBF-LMME, WF-LMME, CF-LMME, and
EAF-LMME to observe their smooth muscle relaxant eﬀects.
Each fraction was added after attaining a stable relation
response to a previous fraction at a time that ranged from
4–9min.
Each freeze-dried fraction was reconstituted by dissolu-
tioninKreb’sRingerBicarbonatebuﬀer(pH7.4)anddiluted
serially (2-fold) with the same buﬀer. Each fraction was
assayed in triplicates at each tested concentration. The ten-
sion attained following contraction induction with nore-
pinephrine and KCl and additions of LMME fractions was
monitored and recorded. Relaxation, a measure of inhibition
of contraction in aorta ring precontracted with either norep-
inephrine or KCl was measured in percentage and calculated
as follows:
Relaxation (Rmax),% =

Tc −Tt
Tc

×100, (2)
where Tc and Tt were tension due to KCl or norepinephrine
(negative control) and an LMME fraction (test). EC50 the
medianeﬀectiveconcentrationwasdeﬁnedastheconcentra-
tion of the fraction required to inhibit aorta contraction by4 Biochemistry Research International
50% of its precontracted state and was obtained by extrapo-
lation from the relaxation-dose curve.
2.6. Statistical Analysis. Data were entered into Microsoft
Excel 2007 and analysis was done using STATA statistical
software version 11.1 (Statacorp, USA). Data were expressed
as mean ± SEM (standard error mean) and percentages
(%). Diﬀerences in mean values of biochemical parameters
investigated between the treatment groups and the control
and involving treatment period were analyzed using Duncan
Multiple range test [37]. Relationship between variables such
as serum total cholesterol and nitric oxide was evaluated by
univariate regression analysis. Outcomes with P value below
0.05 were considered to be signiﬁcant.
3. Results
Induction of contraction of rat aorta ring with 1uM nor-
epinephrine and 80mM KCl was observed to result in ele-
vation of the baseline tension from 1.5g to 1.53 ± 0.07g
and 1.56 ± 0.03g, respectively (results not shown). The n-
butanolfractionoftheL.micranthusmethanolicextract(i.e.,
NBF-LMME) elicited the highest concentration dependent
inhibitory eﬀect on aorta ring contraction due to nore-
pinephrine with an EC50 of 0.65mg/mL and maximum
smooth muscle relaxation (Rmax) of 75.2% (Figure 1).
This was followed 6 by the water fraction (i.e.,
WFLMME) with an EC50 of 1.18mg/mL and Rmax of 56.2%
(Figure 1). The Rmax values for CF-LMME and EAFLMME
were 35.9% and 20.8% with both fractions eliciting EC50
>1.5mg/mL (Figure 1), the maximum tested concentration
for each fraction. On the whole, the disparity in the Rmax
values was signiﬁcant (P = 0.005). The inhibitory eﬀects
of these fractions on KCl-induced aorta contraction also
followed the same order but characterized by lower Rmax
values of 7.1%–28.2% and all fractions eliciting EC50
>1.5mg/mL (Figure 2). On the whole, the disparity in the
Rmax values was signiﬁcant (P = 0.004).
Changes in serum lipid levels in mice administered per
orally 250mg/kg body weight each of the LMME fractions
for 21 days are shown in Table 1. Compared to baseline levels
(day 0), very mild-to-moderate elevation in total cholesterol
levels by 3.4%–7.4% and LDL-cholesterol levels by 30.2–
37.4% that were signiﬁcantly (P<0.05) lower than the
28.6% and 131.9% respective increases in controls, were
found in mice treated with NBF-LMME and WF-LMME.
On day 21, signiﬁcant (P<0.05) reduction in TAG level
(138.5 ± 3.4 versus 152.8 ± 0.6mg/dL) compared to the
control and by 6% when compared with baseline level
147.3 ± 2.5mg/dL) was found in NBF-LMME treated mice.
The disparity observed in HDL-cholesterol levels between
day 0 and day 21 in control and LMME fractions-treated
mice was not signiﬁcant (41.3 ± 0.9v e r s u s4 0 .6–41.6 ±
0.2–0.7mg/dL;P>0.05).
The baseline serum total protein level (5.14 ± 0.05g/dL)
increased by 1.6% in the control and varied by 1.2%–1.7%
after 21 days in mice treated with the LMME fractions, while
serum creatinine elicited alterations that ranged from −8.8%
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Figure 1: Median inhibitory concentration of and relaxation
response to Loranthus micranthus methanolic extract fractions
(LMME) by rat aorta rings precontracted with norepinephrine.
WF-LMME = Water fraction; NBF-LMME = n-butanol fraction;
CF-LMME = chloroform fraction; EAF-LMME = Ethyl acetate
fraction. @P = 0.005, Mulvariate test of mean Rmax values of the
four fractions.
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Figure 2: Median inhibitory concentration of and relaxation
responsetoLoranthusmicranthusmethanolicextract(LMME)frac-
tions by rat aorta rings precontracted with KCl. WF-LMME =
Water fraction; NBF-LMME = n-butanol fraction; CF-LMME =
Chlororform fraction; EAF-LMME = ethyl acetate fraction @P =
0.004 Multivariate test of mean Rmax values of the four fractions.
to 17.6% in the treatment groups (Table 2). These alterations
were not signiﬁcantly diﬀerent (P>0.05) between the
treatment groups and when compared with the control.
However,theNBF-LMME-treatedmiceelicited55%increase
in baseline nitric oxide level (14.9 ± 0.1umole/L) that was
signiﬁcantly higher than 3.7% increase observed in the
control and 2.7%–22.1% increase found in other LMME
fraction-treatment mice (Table 2). Overall, the decreasing
order of potency of the fractions in reducing serum totalBiochemistry Research International 5
Table 1: Changes in serum lipid levels in mice orally administered with the various fractions recovered from Loranthus micranthus
methanolic leaf extract for 21 days.
Treatment group
Control NBF-LMME WF-LMME CF-LMME EAF-LMME
Parameter Day 0 Day 21 Day 21 Day 21 Day 21 Day 21
T-CHOL, mg/dL 88.9 ±0.8a 114.3 ±3.5b 91.9 ±0.4a 95.5 ±2.8c 107.1 ±0.7b 108.9 ±2.8b
%Δ — (28.6) (3.4) (7.4) (20.5) (22.5)
LDL-CHOL, mg/dL 18.2 ±0.3a 42.2 ± 4.3b 23.7 ± 0.9c 25.0 ±3.4c 35.3 ±0.6d 36.1 ±3.1d
%Δ — (131.9) (30.2) (37.4) (94.0) (98.4)
TAG, mg/dL 147.3 ±2.5a 152.8 ±0.6b 138.5 ±3.4c 148.1 ±4.0a 151.9 ±1.2b 152.2 ±2.7b
%Δ — (3.7) (−6.0) (0.5) (3.1) (3.3)
HDL-CHOL, mg/dL 41.3 ±0.9a 41.6 ±0.7a 41.0 ±0.4a 40.8 ±0.7a 41.5 ±0.5a 40.6 ±0.2a
%Δ — (0.7) (−0.7) (−1.2) (0.5) (−1.7)
Data are mean ±SEM of triplicate assays. Figures in each row with diﬀerent superscript letters (a, b, c, d) are signiﬁcantly diﬀerent (P<0.05). Figures in
parentheses represent percentage change (%Δ) in day 21 lipid level compared to day 0 (increase = +; decrease = −). This reﬂects the multiple range test
statistics used to compare the mean values of variables measured across the Loranthus micrathus fraction groups.
Table 2: Changes in cardiac arginase activity and serum total protein, creatinine, and nitric oxide in mice orally administered with the
various fractions recovered from Loranthus micranthus methanolic leaf extract for 21 days.
Treatment group
Control NBF-LMME WF-LMME CF-LMME EAF-LMME
Parameter Day 0 Day 21 Day 21 Day 21 Day 21 Day 21
Total Protein, g/dL 5.14 ±0.05a 5.17 ±0.04a 5.21 ± 0.06a 5.14 ±0.08a 5.22 ±0.02a 5.18 ±0.05a
%Δ — (1.6) (1.2) (0) (1.5) (1.7)
Creatinine, mg/dL 0.34 ±0.04a 0.37 ±0.03a 0.32 ± 0.04a 0.40 ±0.07a 0.31 ±0.07a 0.38 ±0.03a
%Δ — (8.8) (−5.9) (17.6) (−8.8) (11.2)
NO, umole/L 14.9 ± 0.1a 14.5 ±0.6a 23.1 ±1.3b 18.2 ±1.5c 16.1 ±1.8a 15.3 ±0.2a
%Δ — (3.7) (55.0) (22.1) (8.1) (2.7)
Arginase, unit/mg tissue 98.3 ± 3.8a 101.8 ±1.7b 86.8 ±3.5c 90.1 ±1.5d 95.7 ±1.5a 97.1 ±3.4a
%Δ — (3.6) (−11.7) (−8.3) (−2.6) (−1.2)
Data are mean ±SEM of triplicate assays. Figures in each row with diﬀerent superscript letters (a, b, c, d) are signiﬁcantly diﬀerent (P<0.05). Figures in
parentheses represent percentage change (%Δ) in day 21 lipid level compared to day 0 (increase = +; decrease = −). This reﬂects the multiple range test
statistics used to compare the mean values of variables measured across the Loranthus micrathus fraction groups.
cholesterol and triglyceride levels and increasing nitric oxide
level after21 days compared with the controllevels was NBF-
LMME>WF-LMME>CF-LMME>EAF-LMME.TheNBF-
LMME fraction also elicited the highest reduction in cardiac
arginase activity by 11.7%, followed by WF-LMME (8.3%)
(Table 2).
Further analysis indicated that serum total cholesterol
elicited a signiﬁcant (P<0.05) inverse correlation with se-
rum nitric oxide level in mice administered the various frac-
tions of L. micranthus methanolic extract for 21 days such
that a decrease in serum total cholesterol by 1mg/dL would
result in an increase in serum nitric oxide by 0.35umole/L
(Figure 3). This relationship was not found in the control
(Figure 4).
Phytochemical screening of the fractions summarized in
Table 3 showed that high and moderate levels of terpenoids
and steroids were present in the NBF-LMME fraction alone,
while tannins, reducing sugars, and phenolics generally were
in moderate abundance in other fractions. Anthraquinones,
cardiac glycosides were not detected in these fractions, while
saponin and ﬂavonoids were only detected in WF-LMME
andEA-LMME,respectively.Terpenoidswerenotdetectedin
EA-LMME,whileWF-LMMEandCF-LMMEhadmoderate-
to-low levels of these phytoconstituents.
4. Discussion
The results obtained from this study showed that the frac-
tions recovered from L. micranthus methanolic leaf extract
elicited concentration-dependent (0–1.5mg/mL) inhibition
ofnorepinephrineandKCl-inducedrataortasmoothmuscle
contraction with the n-butanol fraction as the most active
fraction followed by water (NBF-LMME), chloroform (CF-
LMME) and ethylacetate (EAF-LMME) fractions. However,
the relaxation eﬀects of these fractions on the aorta smooth
muscle were less pronounced against KCl-induced contrac-
tion compared to norepinephrine. Furthermore, mice given
per orally 250mg/kg bw of the n-butanol fraction also had
the lowest levels of serum total cholesterol, LDL-cholesterol
and triglycerides but highest serum nitric oxide level after
21 days of administrations compared to other fractions and
the control. Norepinephrine is a pressor agent that mediates6 Biochemistry Research International
Table 3: Phytochemical screening of fractions recovered from Loranthus micranthus methanolic leaf extract.
Fractions
Phytoconstituent NBF-LMME WF-LMME CF-LMME EA-LMME
Flavonoids −− − +
Terpenoids +++ ++ + −
Tannins + + ++ +
Phenolics + + ++ +
Saponin − + −−
Anthraquinones −− − −
Cardiac glycosides −− − −
Steroids ++ + −−
Reducing sugars + ++ + +
Abundance indicator: +++ = Highly present; ++ = Moderately present; + = Lowly present; − = Absent.
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Figure 3: Regression analysis showing the relationship between
serum total cholesterol and nitric oxide levels in LMMe-fraction
treated mice for 21 days. Every 1mg/dL decrease in serum total
cholesterol was associated with 0.35umole increase in NO.
smooth muscle contraction via the α-adrenergic receptor
whose activation leads to the activation of phospholipase
C, which in turn produces inositol 1, 4, 5 triphosphate
(IP3) and diacylglycerol (DAG). The consequence of this
cascade is smooth muscle contraction arising from calcium
mobilization from the intracellular store and membrane
depolarization-dependent inﬂux of calcium ion (Ca2+). The
ionotropic response of the aorta smooth muscle to depo-
larizing high KCl (i.e., >30mM) on the hand is mediated
via voltage dependent Ca2+-channels which, opens to allow
an inﬂux of extracellular calcium ions (Ca2+) into smooth
muscle cells for contractility [38].
The observed inhibition of contraction of the aorta ring
in this study implies that our fractions are spasmolytic in
action and antagonistic to the ionotropic eﬀects of nore-
pinephrine, an α-adrenoreceptor agonist. The EC50 and Rmax
values due to the n-butanol fraction against epinephrine-
induced aorta contraction were found to be 0.65mg/mL and
75.2%, respectively. Inhibition of rat aorta smooth muscle
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Figure 4: Regression analysis showing the relationship between
serum total cholesterol and nitric oxide in the control mice.
contraction due to KCl and phenylephrine another α-adren-
ergic receptor agent has also been reported for L. ferrugineus
fractions and the n-butanol fraction was also found to be
the most potent fraction but with a median eﬀective con-
centration (EC50) of 38.4ug/mL and maximum relaxation
(Rmax)e ﬀect of 80.5% against phenylephrine induced con-
traction and EC50 of 726ug/mL and Rmax of 20.7%
against KCl induced contraction [21]. In this study, for
the water and chloroform fractions of L.micranthus,w e
obtained EC50 values of 1.18mg/mL/>1.5mg/mL and
>1.5mg/mL/>1.5mg/mL and Rmax values of 56.5%/10.4%
and 35.9%/10.4% against PE/KCl induced contraction of
the rat aorta smooth muscle, whereas EC50 values of
230ug/mL/8.3ug/mL and 217ug/mL/933ug/mL and Rmax
values of 53.7%/14.3% and 22.4%/6.6% were reported for
these fractions from L. ferrugineus. Although by this result
our fractions can be said to be less potent as spasmolytic
agents compared to replica fractions from L. ferrugineus,
baseline tension of 1.5g was used to equilibrate our aorta
ring preparation and maximum concentration of 1.5mg/mL
for each fraction was tested for spasmolytic eﬀect in this
study.WhereasinthestudyofL.ferrugineus,baselinetensionBiochemistry Research International 7
of 1.0g and maximum concentration of 3.0mg/mL for each
fraction were used [21]. Despite variations in these preload
parameters, disparity in the antiionotropic potency between
L. ferrugineus and L. micranthus may occur, since they
are of a diﬀerent species and may have diﬀerent genetic
background and phytochemistry coupled with the host from
which they propagate as semiparasitic plants. Other plants
with documented evidence for aorta smooth muscle vasore-
laxation include ginger, the ethanolic extracts of Morinda
citrifola root with an EC50 value of 1.65mg/mL against
phenylephrine induced rabbit aorta contraction [39], aque-
ousleafextractofCaesalpiniaferrea[40],andmethanolicleaf
extracts of Croton schiedeanus Schlecht and Calea glomeru-
lata with EC50s of 65ug/mL and 71ug/mL, respectively,
against phenylephrine-induced rat aorta contraction [41].
Thevasorelaxantmechanismadducedfortheseplantsmimic
those of antihypertensive drugs, and they include blockade
of adrenergic receptors, and voltage dependent calcium
channels, inhibition of calcium from intracellular stores, and
opening of voltage; ATP and calcium activate K+ channels
to cause hyperpolarization of smooth muscle membrane
throughfurtherreductionof the resting membrane potential
[39–41]. Similar to our ﬁndings, these plants also relaxed
aorta in a concentration-dependent manner and some of
them were found to inhibit calcium entry slowly and revert
the contractility action mediated by this cation. Therefore,
there is a high possibility that our L. micranthus fractions
may use one or more of these mechanisms. However, there
is a need to study the roles played by these spasmolytic
mechanisms, particularly those that antagonize spasmogenic
actions of norepinephrine. This include α-adrenoreceptor
activation antagonized by adrenoreceptor antagonists such
as papaverine, stimulation of phospholipase C activity that
could be aﬀected using a phosphodiesterase inhibitor, ele-
vation in intracellular IP3 level, intracellular calcium dys-
regulation due to altered activity of endoplasmic reticulum
Ca2+ ATPase and activation of voltage dependent membrane
Calciumchannelthatcouldbeantagonizedbycalciumchan-
n e lb l o c k e r ss u c ha sv e r a p a m i l[ 38].
Another limitation of this study is that the aorta was not
de-endotheliazedtostudytheroleplayedbytheendothelium
since endothelium modulates vascular tone through the
secretion of relaxing substances in which nitric oxide is a
major component [7, 21, 39]. The endothelial nitric oxide
release is in turn dependent on the activation of calcium-
dependent nitric oxide synthase (NOS). The vasodilatory
mechanism of L. ferrugineus fractions was purported to in-
volve this pathway, while Morinda citrifola employed NO-
independent pathways to mediate vasodilatory response in
rabbit aorta smooth muscle [39].
Nevertheless, our observed higher serum NO levels but
lower total cholesterol, LDL-cholesterol and TAG levels
particularly in mice administered NBF-LMME and WF-
LMME after 21 days of administration compared to the con-
trol provides an indication that these fractions contain
antiartherogenic and vascular modulating substances. Ar-
ginase has been considered to be a diagnostic indicator for
hypertension and other cardiovascular diseases [42]. Higher
activity has been found to reduce arginine bioavailability
as substrate for NOS in the endothelium, the pathologic
consequences of which include increased vascular resistance,
blood pressure and arthropathy [42, 43]. In this study, the
NBF-LMME fraction was found to elicit a reduction in
cardiac arginase by 11.7% of the control after 21 days of
administration in our studied mice, while the water fraction
caused8.3%reductioninthisenzymeactivity.Therefore,our
observation suggests arginase activity reduction as a possible
antihypertensive mechanism of L. micranthus and further
identify the n-butanol fraction as a better source antihy-
pertensive principle in the plant. Cardiac arginase has been
reported to be hemodynamically sensitive to blood pressure
ﬂuctuations and arginase inhibitors such as hydrazalazine
and nor hydroxyl arginine have been demonstrated to hold
promise as future antihypertensive agents courtesy of their
abilities to cause reduction in arginase activity by up to 30%
and arterial blood pressure by 30–35mmHg, modulate
arterial resistance and promote blood ﬂow [42, 43]. It is
important to note that cardiovascular diseases such as hyper-
tension, arrythmias, angina pectoris, myocardial infarction,
stroke,andleftventricularhypertrophyhavebecomeamajor
cause of morbidity and mortality in the world with increas-
ing prevalence in developing countries [44]. Hypercholes-
terolemia, hypertriglyceridemia, elevated LDL-cholesterol
andendothelialdysfunctionhavebeenrecognizedasriskfac-
tors of these diseases [45, 46]. Cholesterol and triglycerides
are hydrophobic and are transported in systemic circulation
through packaging in LDL-cholesterol, and very low density
lipoprotein [46, 47]. Elevated levels of these lipids have been
associated with age and consumption of high lipid diets
[48]. These lipids are artherogenic because they enhance
narrowing of the blood to retard blood ﬂow and increase
vascular resistance [48]. In severe cases, the ﬂow of blood
is completely blocked causing tissue ischaemia and necrosis
[49]. The narrowing of the blood vessels is as a result of
plaque formation involving artherogenic lipid modiﬁcation
by peroxidation and proliferation of underlying smooth cells
and foam cell formation coupled with nitric oxide con-
sumption to form reactive nitrogen species (RON) and
release of adhesion molecules with vasoconstriction eﬀect
into the systemic circulation [49]. Therefore, diet modiﬁca-
tion, exercise, use of hypocholesterolemic and triglyceride-
lowering drugs are key therapeutic options for the man-
agement of arthrosclerosis and other cardiovascular diseases
[48].
However, in this study we found no signiﬁcant diﬀerence
between the control and fraction-treated mice in the levels
of HDL-cholesterol, creatinine and total protein suggesting
that the antiartherogenic property of our fractions may not
involve HDL-cholesterol elevation, and altered kidney and
liver functions to modulate nitric oxide excretion or reten-
tion and enhance synthesis of secreted proteins.
Taken together, our ﬁndings indicate that L. micranthus
possesses hypocholesterolemic, hypotriglyceridemic, and
antioxidantsubstancesinadditiontoitseﬀectonnitricoxide
metabolism. The results of this study have also validated the
previousantihypertensiveclaimsforthisplantinNigeriaand
South Africa [15–17].8 Biochemistry Research International
Furthermore, we found steroids and terpenoids in mod-
erate and high abundance in the n-butanol fraction, while
tannins and other phenolic compounds were found to be
mildly present in this fraction and the water fraction. These
ﬁndings strongly suggest the possibility of involvement of
these phytoconstituents in the observed vasorelaxant and
antiartherogenic activity of our active fractions. There is also
a possibility for noninvolvement of ﬂavonoids in these activ-
ities since it was only detected in the ethylacetate fraction.
Chromatographic peaks suggesting terpenoid abundance
wasfoundasthemajorbioactivesubstancethatmediatedthe
vasorelaxant and antihypertensive activity of the n-butanol
fraction of L. ferrugineus methanolic extract [21], while tan-
nins, Flavonoids, anthraquinones and steroids were impli-
cated as vasorelaxant, antihypertensive and antidiabetic sub-
stances in Morinda citrifola [39]. In the work of Nishida and
Satoh [50], Flavonoids and Terpenoids were implicated as
vasorelaxant agents in Ginkgo biloba. These substances have
also been detected in the crude aqueous and methanolic leaf
extracts of L. micranthus, suggesting that by solvent-solvent
fractionation, these substances are partitioned and concen-
trated in diﬀerent fractions. Our ﬁndings, thus, indicate
that the bioactive substances involved in the cardiovascular
activity of L. micranthus are polar in nature. However, the
possibility of noninvolvement of ﬂavonoids needs further
conﬁrmation with more sensitive methods.
Based on the results obtained so far in this study, we
concludethatthepreviouslyreportedantihypertensiveactiv-
ity of L. micranthus mechanistically involve vasorelaxation,
elevation of serum nitric oxide, and antiartherogenic eﬀect
against systemic triglyceride and cholesterol levels in mice
with terpenoids, steroids, and tannins as potential bioactive
substances mediating these mechanisms.
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